All In Biotech

Drug Trial Radar · NCT06462365

Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

Phase I, First in Human, Open Label Study to Evaluate Safety and Tolerability of TRX103 Cells in Subjects With Hematological Malignancies Undergoing HLA-mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT)

Last checked: Nov 19, 2026Latest source record: Apr 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Apr 8, 2024

Primary completion

Apr 15, 2026

Study completion Apr 15, 2027

Sponsor

Lead sponsor
Tr1X, Inc.Industry
Sponsor type
Industry
First posted
Jun 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT). It is anticipated that up to 36 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time post HSCT.

Conditions

  • Hematologic Malignancy
  • GvHD
  • GVHD,Acute
  • GVHD, Chronic
  • Hematopoietic Stem Cell Transplant
  • Acute Lymphoblastic Leukemia, Adult B-Cell
  • Acute Lymphoblastic Leukemia, Adult T-Cell
  • Acute Myeloid Leukemia in Remission
  • Myelodysplastic Syndromes
  • Chronic Myelomonocytic Leukemia, in Remission
  • Cancer Remission

Interventions

  • TRX103Biological

    TRX103 infusion via central line.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of TRX103 cell infusion through incidence of Adverse events.Time frame: Up to a year
  2. Safety of TRX103 determined by stem cell engraftment and donor chimerism after HSCT measured by absolute neutrophil counts and percent donor chimerism.Time frame: Up to day 42
  3. Safety of TRX103 determined by negative Replication Competent Lentivirus (RCL).Time frame: At 3-month, 6-month, and 1-year.

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.